John Kane
British actor and writer
3
APPEARANCES
3
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
Aug 13, 2026
Keeping Pace with a Changing Reimbursement Landscape
17:42
J
8:26John KaneGUEST
Talk about operating from within a silo and the potential downstream effects of that type of approach.
J
8:33John KaneGUEST
Again, I feel a great amount of pride for how we constructed and implemented PDPM, but I have to admit a complete and utter blindness to the impact that this was going to have on states.
J
8:46John KaneGUEST
And I think this really goes back to the structural siloing of CMS and its impact on policy development.
J
8:52John KaneGUEST
To put a really fine point on it, I didn't really have a lot of conversations with the Medicaid side of CMS until PDPM was about to be implemented.
J
9:05John KaneGUEST
It was mine, and it was the responsibility of those of us who were developing this policy.
9 MINS LATER

Debbie StadtlerHOST
Where do you see the SNF and assisted living sectors headed when it comes to reimbursement and financial viability? And what do providers need to do to stay competitive?
Inside Pharmacovigilance: Detecting Risks, Protecting Patients
J
4:59Jeremy ShranHOST
So for listeners who have may be unfamiliar with what pharmacovigilance is, can you explain it and why it's so important in clinical research?
J
5:14John KaneGUEST
I like to give a scenario where CTI has been working with a pharma company for the entirety of a drug development.
J
5:20John KaneGUEST
We started in Phase I, first in human, making it to Phase II, Phase III, and finally on to market.
J
5:26John KaneGUEST
Then when somebody goes and gets this drug prescribed, picks it up from their pharmacist, they're gonna have a package insert in there, prescribing information.
J
5:33John KaneGUEST
Generally a big sheet of paper, tiny little writing, with all sorts of information about that drug.
J
7:42Jeremy ShranHOST
How does CTI safety and pharmacovigilance team protect patients throughout the drug development process?
Chamber Legislative Forum 6-2-2026
19 MINS LATER
